Ontak denileukin diftitox: Phase II data

In the open-label, U.S. Phase II CONCEPT trial in 49 patients with newly-diagnosed PTCL, Ontak plus CHOP chemotherapy produced an ORR of 65%, with 51% of patients achieving a complete response (CR). I...